You are using an unsupported browser. Please upgrade your browser to a newer version to get the best experience on DrugBank.
Identification
NameTocilizumab
Accession NumberDB06273
TypeBiotech
GroupsApproved
DescriptionTocilizumab is a recombinant, humanized, anti-human interleukin 6 (IL-6) receptor monoclonal antibody that achieves a significant therapeutic response rate. The light chain is made up of 214 amino acids. The heavy chain is made up of 448 amino acids. The four polypeptide chains are linked intra- and inter-molecularly by disulfide bonds. FDA approved on January 8, 2010.
Protein structureDb06273
Related Articles
Protein chemical formulaC6428H9976N1720O2018S42
Protein average weight148000.0 Da
SequencesNot Available
Synonyms
Atlizumab
MRA
RoActemra®
External Identifiers
  • R-1569
Approved Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Actemrasolution162 mgsubcutaneousHoffmann La Roche Limited2014-05-30Not applicableCanada
Actemrainjection, solution, concentrate20 mg/mLintravenousGenentech, Inc.2010-01-08Not applicableUs
Actemrasolution80 mgintravenousHoffmann La Roche Limited2010-05-26Not applicableCanada
Actemrainjection, solution, concentrate20 mg/mLintravenousGenentech, Inc.2010-01-08Not applicableUs
Actemrasolution200 mgintravenousHoffmann La Roche Limited2010-05-26Not applicableCanada
Actemrainjection, solution, concentrate20 mg/mLintravenousGenentech, Inc.2010-01-08Not applicableUs
Actemrasolution400 mgintravenousHoffmann La Roche Limited2010-05-26Not applicableCanada
Actemrainjection, solution180 mg/mLsubcutaneousGenentech, Inc.2013-10-21Not applicableUs
Approved Generic Prescription ProductsNot Available
Approved Over the Counter ProductsNot Available
Unapproved/Other Products Not Available
International BrandsNot Available
Brand mixturesNot Available
SaltsNot Available
Categories
UNIII031V2H011
CAS number375823-41-9
Taxonomy
DescriptionNot Available
KingdomOrganic Compounds
Super ClassOrganic Acids
ClassCarboxylic Acids and Derivatives
Sub ClassAmino Acids, Peptides, and Analogues
Direct ParentPeptides
Alternative ParentsNot Available
SubstituentsNot Available
Molecular FrameworkNot Available
External DescriptorsNot Available
Pharmacology
IndicationIndicated for the treatment of adult patients with moderately to severely active rheumatoid arthritis (RA) who have had an inadequate response to one or more Disease-Modifying Anti-Rheumatic Drugs (DMARDs). It is also indicated for the treatment of active polyarticular juvenile idiopathic arthritis (PJIA) and active systemic juvenile idiopathic arthritis (SJIA) in patients 2 years of age and older.
PharmacodynamicsA decrease in C-reactive protein (CRP) was noted as early as week 2. Changes in pharmacodynamic parameters were observed (i.e., decreases in rheumatoid factor, erythrocyte sedimentation rate (ESR), serum amyloid A and increases in hemoglobin) with both doses, however the greatest improvements were observed with 8 mg per kg tocilizumab. Similar pharmacodynamic changes were also observed in active polyarticular juvenile idiopathic arthritis and active systemic juvenile idiopathic arthritis patients.
Mechanism of actionInterleukin (IL)-6 plays essential roles not only in the immune response, but also in haematopoiesis and the central nervous system. Deregulated production of IL-6 has been found in chronic inflammatory autoimmune diseases, such as rheumatoid arthritis (RA), systemic onset juvenile idiopathic arthritis (soJIA), Crohn's disease (CD) and systemic lupus erythematosus (SLE). Furthermore, IL-6 activities can explain many symptoms of these diseases. More importantly, serum levels of IL-6 are correlated with disease activity. Tocilizumab binds specifically to both soluble and membrane-bound IL-6 receptors (sIL-6R and mIL-6R), and has been shown to inhibit IL-6-mediated signaling through these receptors.
Related Articles
AbsorptionWhen 4 mg/kg of tocilizumab was given every 4 weeks to RA patients, the pharmacokinetic parameters at steady state are as follows: AUC = 13000 ± 5800 mcg∙h/mL; Cmax = 88.3 ± 41.4 mcg/mL. Tocilizumab accumulates following repeated doses. Furthermore, an increased body weight may increase plasma levels of tocilizumab. When a dose of 8 mg/kg of tocilizumab is given to PJIA patients, the pharmacokinetic parameters are as follows: AUC = 29500 ± 8660 mcg∙h/mL; Cmax = 182 ± 37 mcg/mL. When a dose of 8 mg/kg of tocilizumab is given to SJIA patients, the pharmacokinetic parameters are as follows: AUC = 32200 ± 9960 mcg∙h/mL; Cmax = 245 ± 57.2 mcg/mL.
Volume of distribution

In rheumatoid arthritis patients the central volume of distribution was 3.5 L and the peripheral volume of distribution was 2.9 L, resulting in a volume of distribution at steady state of 6.4 L.

In pediatric patients with PJIA, the central volume of distribution was 1.98 L, the peripheral volume of distribution was 2.1 L, resulting in a volume of distribution at steady state of 4.08 L.

In pediatric patients with SJIA, the central volume of distribution was 0.94 L, the peripheral volume of distribution was 1.60 L resulting in a volume of distribution at steady state of 2.54 L.

Protein bindingNot Available
MetabolismNot Available
Route of eliminationFollowing intravenous dosing, tocilizumab undergoes biphasic elimination from the circulation.
Half lifeThe half-life of tocilizumab is concentration-dependent. The concentration-dependent apparent half-life is up to 11 days for 4 mg/kg and up to 13 days for 8 mg/kg every 4 weeks in patients with RA at steady-state. The half-life in children with PJIA is up to 16 days. The half-life in pediatric patients with SJIA is up to 23 days.
Clearance

The clearance of tocilizumab decreases with increasing dose. At the 10 mg/kg single dose in RA patients, mean clearance was 0.29 ± 0.10 mL/hr/kg. The total clearance of tocilizumab is concentration-dependent and is the sum of the linear clearance and the nonlinear clearance. At low concentrations, concentration-dependent nonlinear clearance is dominant. At high concentrations, linear clearance dominates. The estimated linear clearances for specific patient populations are as follows:
RA = 12.5 mL/h;
PJIA, pediatric patients = 5.8 mL/h;
SJIA, pediatric patients = 7.1 mL/h.

ToxicityMost common adverse reactions (incidence of at least 5%): upper respiratory tract infections, nasopharyngitis, headache, hypertension, increased ALT.
Affected organisms
  • Humans and other mammals
PathwaysNot Available
SNP Mediated EffectsNot Available
SNP Mediated Adverse Drug ReactionsNot Available
Pharmacoeconomics
ManufacturersNot Available
PackagersNot Available
Dosage forms
FormRouteStrength
Injection, solutionsubcutaneous180 mg/mL
Injection, solution, concentrateintravenous20 mg/mL
Solutionintravenous200 mg
Solutionintravenous400 mg
Solutionintravenous80 mg
Solutionsubcutaneous162 mg
PricesNot Available
Patents
Patent NumberPediatric ExtensionApprovedExpires (estimated)
CA1341152 No2000-12-122017-12-12Canada
CA2201781 No2010-01-122015-06-07Canada
Properties
StateLiquid
Experimental PropertiesNot Available
References
Synthesis ReferenceNot Available
General References
  1. Mihara M, Nishimoto N, Ohsugi Y: The therapy of autoimmune diseases by anti-interleukin-6 receptor antibody. Expert Opin Biol Ther. 2005 May;5(5):683-90. [PubMed:15934843 ]
External Links
ATC CodesL04AC07
AHFS Codes
  • 92:36
PDB EntriesNot Available
FDA labelDownload (623 KB)
MSDSDownload (482 KB)
Interactions
Drug Interactions
Drug
AbataceptThe risk or severity of adverse effects can be increased when Tocilizumab is combined with Abatacept.
AbirateroneThe serum concentration of Abiraterone can be decreased when it is combined with Tocilizumab.
AcenocoumarolThe serum concentration of Acenocoumarol can be decreased when it is combined with Tocilizumab.
AcetaminophenThe serum concentration of Acetaminophen can be decreased when it is combined with Tocilizumab.
AdalimumabTocilizumab may increase the immunosuppressive activities of Adalimumab.
AdinazolamThe serum concentration of Adinazolam can be decreased when it is combined with Tocilizumab.
AfelimomabTocilizumab may increase the immunosuppressive activities of Afelimomab.
AlbendazoleThe serum concentration of Albendazole can be decreased when it is combined with Tocilizumab.
AlclometasoneThe serum concentration of Alclometasone can be decreased when it is combined with Tocilizumab.
AlfentanilThe serum concentration of Alfentanil can be decreased when it is combined with Tocilizumab.
AlfuzosinThe serum concentration of Alfuzosin can be decreased when it is combined with Tocilizumab.
AliskirenThe serum concentration of Aliskiren can be decreased when it is combined with Tocilizumab.
AllylestrenolThe serum concentration of Allylestrenol can be decreased when it is combined with Tocilizumab.
AlmotriptanThe serum concentration of Almotriptan can be decreased when it is combined with Tocilizumab.
AlogliptinThe serum concentration of Alogliptin can be decreased when it is combined with Tocilizumab.
AlosetronThe serum concentration of Alosetron can be decreased when it is combined with Tocilizumab.
AlprazolamThe serum concentration of Alprazolam can be decreased when it is combined with Tocilizumab.
AmbrisentanThe serum concentration of Ambrisentan can be decreased when it is combined with Tocilizumab.
AmbroxolThe serum concentration of Ambroxol can be decreased when it is combined with Tocilizumab.
AminophenazoneThe serum concentration of Aminophenazone can be decreased when it is combined with Tocilizumab.
AminophyllineThe serum concentration of Aminophylline can be decreased when it is combined with Tocilizumab.
AmiodaroneThe serum concentration of Amiodarone can be decreased when it is combined with Tocilizumab.
AmitriptylineThe serum concentration of Amitriptyline can be decreased when it is combined with Tocilizumab.
AmlodipineThe serum concentration of Amlodipine can be decreased when it is combined with Tocilizumab.
AmprenavirThe serum concentration of Amprenavir can be decreased when it is combined with Tocilizumab.
AntipyrineThe serum concentration of Antipyrine can be decreased when it is combined with Tocilizumab.
ApixabanThe serum concentration of Apixaban can be decreased when it is combined with Tocilizumab.
ApremilastThe serum concentration of Apremilast can be decreased when it is combined with Tocilizumab.
AprepitantThe serum concentration of Aprepitant can be decreased when it is combined with Tocilizumab.
ArgatrobanThe serum concentration of Argatroban can be decreased when it is combined with Tocilizumab.
AripiprazoleThe serum concentration of Aripiprazole can be decreased when it is combined with Tocilizumab.
ArtemetherThe serum concentration of Artemether can be decreased when it is combined with Tocilizumab.
AsenapineThe serum concentration of Asenapine can be decreased when it is combined with Tocilizumab.
AstemizoleThe serum concentration of Astemizole can be decreased when it is combined with Tocilizumab.
AtazanavirThe serum concentration of Atazanavir can be decreased when it is combined with Tocilizumab.
AtorvastatinThe serum concentration of Atorvastatin can be decreased when it is combined with Tocilizumab.
AvanafilThe serum concentration of Avanafil can be decreased when it is combined with Tocilizumab.
AxitinibThe serum concentration of Axitinib can be decreased when it is combined with Tocilizumab.
AzelastineThe serum concentration of Azelastine can be decreased when it is combined with Tocilizumab.
AzithromycinThe serum concentration of Azithromycin can be decreased when it is combined with Tocilizumab.
BanoxantroneThe serum concentration of Banoxantrone can be decreased when it is combined with Tocilizumab.
BedaquilineThe serum concentration of Bedaquiline can be decreased when it is combined with Tocilizumab.
BenzphetamineThe serum concentration of Benzphetamine can be decreased when it is combined with Tocilizumab.
Benzyl alcoholThe serum concentration of Benzyl alcohol can be decreased when it is combined with Tocilizumab.
BexaroteneThe serum concentration of Bexarotene can be decreased when it is combined with Tocilizumab.
BezafibrateThe serum concentration of Bezafibrate can be decreased when it is combined with Tocilizumab.
BicalutamideThe serum concentration of Bicalutamide can be decreased when it is combined with Tocilizumab.
BisoprololThe serum concentration of Bisoprolol can be decreased when it is combined with Tocilizumab.
BoceprevirThe serum concentration of Boceprevir can be decreased when it is combined with Tocilizumab.
BortezomibThe serum concentration of Bortezomib can be decreased when it is combined with Tocilizumab.
BosentanThe serum concentration of Bosentan can be decreased when it is combined with Tocilizumab.
BosutinibThe serum concentration of Bosutinib can be decreased when it is combined with Tocilizumab.
Brentuximab vedotinThe serum concentration of Brentuximab vedotin can be decreased when it is combined with Tocilizumab.
BrexpiprazoleThe serum concentration of Brexpiprazole can be decreased when it is combined with Tocilizumab.
BrinzolamideThe serum concentration of Brinzolamide can be decreased when it is combined with Tocilizumab.
BromazepamThe serum concentration of Bromazepam can be decreased when it is combined with Tocilizumab.
BromocriptineThe serum concentration of Bromocriptine can be decreased when it is combined with Tocilizumab.
BrompheniramineThe serum concentration of Brompheniramine can be decreased when it is combined with Tocilizumab.
BudesonideThe serum concentration of Budesonide can be decreased when it is combined with Tocilizumab.
BupivacaineThe serum concentration of Bupivacaine can be decreased when it is combined with Tocilizumab.
BuprenorphineThe serum concentration of Buprenorphine can be decreased when it is combined with Tocilizumab.
BupropionThe serum concentration of Bupropion can be decreased when it is combined with Tocilizumab.
BuspironeThe serum concentration of Buspirone can be decreased when it is combined with Tocilizumab.
BusulfanThe serum concentration of Busulfan can be decreased when it is combined with Tocilizumab.
CabazitaxelThe serum concentration of Cabazitaxel can be decreased when it is combined with Tocilizumab.
CabergolineThe serum concentration of Cabergoline can be decreased when it is combined with Tocilizumab.
CabozantinibThe serum concentration of Cabozantinib can be decreased when it is combined with Tocilizumab.
CaffeineThe serum concentration of Caffeine can be decreased when it is combined with Tocilizumab.
CalcitriolThe serum concentration of Calcitriol can be decreased when it is combined with Tocilizumab.
CanagliflozinThe serum concentration of Canagliflozin can be decreased when it is combined with Tocilizumab.
CarbamazepineThe serum concentration of Carbamazepine can be decreased when it is combined with Tocilizumab.
CarbinoxamineThe serum concentration of Carbinoxamine can be decreased when it is combined with Tocilizumab.
CariprazineThe serum concentration of Cariprazine can be decreased when it is combined with Tocilizumab.
CarvedilolThe serum concentration of Carvedilol can be decreased when it is combined with Tocilizumab.
CelecoxibThe serum concentration of Celecoxib can be decreased when it is combined with Tocilizumab.
CeliprololThe serum concentration of Celiprolol can be decreased when it is combined with Tocilizumab.
CephalexinThe serum concentration of Cephalexin can be decreased when it is combined with Tocilizumab.
CerivastatinThe serum concentration of Cerivastatin can be decreased when it is combined with Tocilizumab.
Certolizumab pegolTocilizumab may increase the immunosuppressive activities of Certolizumab pegol.
CevimelineThe serum concentration of Cevimeline can be decreased when it is combined with Tocilizumab.
Chenodeoxycholic acidThe serum concentration of Chenodeoxycholic acid can be decreased when it is combined with Tocilizumab.
ChlordiazepoxideThe serum concentration of Chlordiazepoxide can be decreased when it is combined with Tocilizumab.
ChloroquineThe serum concentration of Chloroquine can be decreased when it is combined with Tocilizumab.
ChlorphenamineThe serum concentration of Chlorphenamine can be decreased when it is combined with Tocilizumab.
ChlorpromazineThe serum concentration of Chlorpromazine can be decreased when it is combined with Tocilizumab.
ChlorzoxazoneThe serum concentration of Chlorzoxazone can be decreased when it is combined with Tocilizumab.
CholecalciferolThe serum concentration of Cholecalciferol can be decreased when it is combined with Tocilizumab.
CiclesonideThe serum concentration of Ciclesonide can be decreased when it is combined with Tocilizumab.
CilostazolThe serum concentration of Cilostazol can be decreased when it is combined with Tocilizumab.
CinacalcetThe serum concentration of Cinacalcet can be decreased when it is combined with Tocilizumab.
CisaprideThe serum concentration of Cisapride can be decreased when it is combined with Tocilizumab.
CitalopramThe serum concentration of Citalopram can be decreased when it is combined with Tocilizumab.
ClarithromycinThe serum concentration of Clarithromycin can be decreased when it is combined with Tocilizumab.
ClindamycinThe serum concentration of Clindamycin can be decreased when it is combined with Tocilizumab.
ClobazamThe serum concentration of Clobazam can be decreased when it is combined with Tocilizumab.
ClofazimineThe serum concentration of Clofazimine can be decreased when it is combined with Tocilizumab.
ClofibrateThe serum concentration of Clofibrate can be decreased when it is combined with Tocilizumab.
clomethiazoleThe serum concentration of clomethiazole can be decreased when it is combined with Tocilizumab.
ClomipramineThe serum concentration of Clomipramine can be decreased when it is combined with Tocilizumab.
ClonazepamThe serum concentration of Clonazepam can be decreased when it is combined with Tocilizumab.
ClonidineThe serum concentration of Clonidine can be decreased when it is combined with Tocilizumab.
ClopidogrelThe serum concentration of Clopidogrel can be decreased when it is combined with Tocilizumab.
ClorazepateThe serum concentration of Clorazepate can be decreased when it is combined with Tocilizumab.
ClotiazepamThe serum concentration of Clotiazepam can be decreased when it is combined with Tocilizumab.
ClozapineThe serum concentration of Clozapine can be decreased when it is combined with Tocilizumab.
CocaineThe serum concentration of Cocaine can be decreased when it is combined with Tocilizumab.
CodeineThe serum concentration of Codeine can be decreased when it is combined with Tocilizumab.
ColchicineThe serum concentration of Colchicine can be decreased when it is combined with Tocilizumab.
ConivaptanThe serum concentration of Conivaptan can be decreased when it is combined with Tocilizumab.
Conjugated Equine EstrogensThe serum concentration of Conjugated Equine Estrogens can be decreased when it is combined with Tocilizumab.
Cortisone acetateThe serum concentration of Cortisone acetate can be decreased when it is combined with Tocilizumab.
CrizotinibThe serum concentration of Crizotinib can be decreased when it is combined with Tocilizumab.
CyclobenzaprineThe serum concentration of Cyclobenzaprine can be decreased when it is combined with Tocilizumab.
CyclophosphamideThe serum concentration of Cyclophosphamide can be decreased when it is combined with Tocilizumab.
CyclosporineThe serum concentration of Cyclosporine can be decreased when it is combined with Tocilizumab.
CytarabineThe serum concentration of Cytarabine can be decreased when it is combined with Tocilizumab.
DabrafenibThe serum concentration of Dabrafenib can be decreased when it is combined with Tocilizumab.
DaclatasvirThe serum concentration of Daclatasvir can be decreased when it is combined with Tocilizumab.
DantroleneThe serum concentration of Dantrolene can be decreased when it is combined with Tocilizumab.
DapagliflozinThe serum concentration of Dapagliflozin can be decreased when it is combined with Tocilizumab.
DapsoneThe serum concentration of Dapsone can be decreased when it is combined with Tocilizumab.
DarifenacinThe serum concentration of Darifenacin can be decreased when it is combined with Tocilizumab.
DarunavirThe serum concentration of Darunavir can be decreased when it is combined with Tocilizumab.
DasabuvirThe serum concentration of Dasabuvir can be decreased when it is combined with Tocilizumab.
DasatinibThe serum concentration of Dasatinib can be decreased when it is combined with Tocilizumab.
DaunorubicinThe serum concentration of Daunorubicin can be decreased when it is combined with Tocilizumab.
DehydroepiandrosteroneThe serum concentration of Dehydroepiandrosterone can be decreased when it is combined with Tocilizumab.
DelavirdineThe serum concentration of Delavirdine can be decreased when it is combined with Tocilizumab.
DenosumabThe risk or severity of adverse effects can be increased when Denosumab is combined with Tocilizumab.
DesvenlafaxineThe serum concentration of Desvenlafaxine can be decreased when it is combined with Tocilizumab.
DexamethasoneThe serum concentration of Dexamethasone can be decreased when it is combined with Tocilizumab.
DextromethorphanThe serum concentration of Dextromethorphan can be decreased when it is combined with Tocilizumab.
DextropropoxypheneThe serum concentration of Dextropropoxyphene can be decreased when it is combined with Tocilizumab.
DiazepamThe serum concentration of Diazepam can be decreased when it is combined with Tocilizumab.
DiclofenacThe serum concentration of Diclofenac can be decreased when it is combined with Tocilizumab.
DigitoxinThe serum concentration of Digitoxin can be decreased when it is combined with Tocilizumab.
DigoxinThe serum concentration of Digoxin can be decreased when it is combined with Tocilizumab.
DihydrocodeineThe serum concentration of Dihydrocodeine can be decreased when it is combined with Tocilizumab.
DihydroergotamineThe serum concentration of Dihydroergotamine can be decreased when it is combined with Tocilizumab.
DiltiazemThe serum concentration of Diltiazem can be decreased when it is combined with Tocilizumab.
DisopyramideThe serum concentration of Disopyramide can be decreased when it is combined with Tocilizumab.
DisulfiramThe serum concentration of Disulfiram can be decreased when it is combined with Tocilizumab.
DocetaxelThe serum concentration of Docetaxel can be decreased when it is combined with Tocilizumab.
DofetilideThe serum concentration of Dofetilide can be decreased when it is combined with Tocilizumab.
DolasetronThe serum concentration of Dolasetron can be decreased when it is combined with Tocilizumab.
DomperidoneThe serum concentration of Domperidone can be decreased when it is combined with Tocilizumab.
DonepezilThe serum concentration of Donepezil can be decreased when it is combined with Tocilizumab.
DorzolamideThe serum concentration of Dorzolamide can be decreased when it is combined with Tocilizumab.
DoxepinThe serum concentration of Doxepin can be decreased when it is combined with Tocilizumab.
DoxorubicinThe serum concentration of Doxorubicin can be decreased when it is combined with Tocilizumab.
DronabinolThe serum concentration of Dronabinol can be decreased when it is combined with Tocilizumab.
DronedaroneThe serum concentration of Dronedarone can be decreased when it is combined with Tocilizumab.
DutasterideThe serum concentration of Dutasteride can be decreased when it is combined with Tocilizumab.
EfavirenzThe serum concentration of Efavirenz can be decreased when it is combined with Tocilizumab.
EletriptanThe serum concentration of Eletriptan can be decreased when it is combined with Tocilizumab.
EliglustatThe serum concentration of Eliglustat can be decreased when it is combined with Tocilizumab.
ElvitegravirThe serum concentration of Elvitegravir can be decreased when it is combined with Tocilizumab.
EnalaprilThe serum concentration of Enalapril can be decreased when it is combined with Tocilizumab.
EnzalutamideThe serum concentration of Enzalutamide can be decreased when it is combined with Tocilizumab.
EpinastineThe serum concentration of Epinastine can be decreased when it is combined with Tocilizumab.
EplerenoneThe serum concentration of Eplerenone can be decreased when it is combined with Tocilizumab.
ErgocalciferolThe serum concentration of Ergocalciferol can be decreased when it is combined with Tocilizumab.
Ergoloid mesylateThe serum concentration of Ergoloid mesylate can be decreased when it is combined with Tocilizumab.
ErgonovineThe serum concentration of Ergonovine can be decreased when it is combined with Tocilizumab.
ErgotamineThe serum concentration of Ergotamine can be decreased when it is combined with Tocilizumab.
ErlotinibThe serum concentration of Erlotinib can be decreased when it is combined with Tocilizumab.
ErythromycinThe serum concentration of Erythromycin can be decreased when it is combined with Tocilizumab.
EscitalopramThe serum concentration of Escitalopram can be decreased when it is combined with Tocilizumab.
EsomeprazoleThe serum concentration of Esomeprazole can be decreased when it is combined with Tocilizumab.
EstazolamThe serum concentration of Estazolam can be decreased when it is combined with Tocilizumab.
EstradiolThe serum concentration of Estradiol can be decreased when it is combined with Tocilizumab.
Estradiol valerate/DienogestThe serum concentration of Estradiol valerate/Dienogest can be decreased when it is combined with Tocilizumab.
EstramustineThe serum concentration of Estramustine can be decreased when it is combined with Tocilizumab.
EstroneThe serum concentration of Estrone can be decreased when it is combined with Tocilizumab.
Estrone sulfateThe serum concentration of Estrone sulfate can be decreased when it is combined with Tocilizumab.
EszopicloneThe serum concentration of Eszopiclone can be decreased when it is combined with Tocilizumab.
EtanerceptTocilizumab may increase the immunosuppressive activities of Etanercept.
EthanolThe serum concentration of Ethanol can be decreased when it is combined with Tocilizumab.
Ethinyl EstradiolThe serum concentration of Ethinyl Estradiol can be decreased when it is combined with Tocilizumab.
EthosuximideThe serum concentration of Ethosuximide can be decreased when it is combined with Tocilizumab.
EthylmorphineThe serum concentration of Ethylmorphine can be decreased when it is combined with Tocilizumab.
EtonogestrelThe serum concentration of Etonogestrel can be decreased when it is combined with Tocilizumab.
EtoposideThe serum concentration of Etoposide can be decreased when it is combined with Tocilizumab.
EtoricoxibThe serum concentration of Etoricoxib can be decreased when it is combined with Tocilizumab.
EtravirineThe serum concentration of Etravirine can be decreased when it is combined with Tocilizumab.
EverolimusThe serum concentration of Everolimus can be decreased when it is combined with Tocilizumab.
ExemestaneThe serum concentration of Exemestane can be decreased when it is combined with Tocilizumab.
FamciclovirThe serum concentration of Famciclovir can be decreased when it is combined with Tocilizumab.
FelbamateThe serum concentration of Felbamate can be decreased when it is combined with Tocilizumab.
FelodipineThe serum concentration of Felodipine can be decreased when it is combined with Tocilizumab.
FenofibrateThe serum concentration of Fenofibrate can be decreased when it is combined with Tocilizumab.
FentanylThe serum concentration of Fentanyl can be decreased when it is combined with Tocilizumab.
FesoterodineThe serum concentration of Fesoterodine can be decreased when it is combined with Tocilizumab.
FinasterideThe serum concentration of Finasteride can be decreased when it is combined with Tocilizumab.
FingolimodThe serum concentration of Fingolimod can be decreased when it is combined with Tocilizumab.
FlibanserinThe serum concentration of Flibanserin can be decreased when it is combined with Tocilizumab.
FlunisolideThe serum concentration of Flunisolide can be decreased when it is combined with Tocilizumab.
FlunitrazepamThe serum concentration of Flunitrazepam can be decreased when it is combined with Tocilizumab.
FluorometholoneThe serum concentration of Fluorometholone can be decreased when it is combined with Tocilizumab.
FluoxetineThe serum concentration of Fluoxetine can be decreased when it is combined with Tocilizumab.
FlurazepamThe serum concentration of Flurazepam can be decreased when it is combined with Tocilizumab.
FlutamideThe serum concentration of Flutamide can be decreased when it is combined with Tocilizumab.
Fluticasone furoateThe serum concentration of Fluticasone furoate can be decreased when it is combined with Tocilizumab.
Fluticasone PropionateThe serum concentration of Fluticasone Propionate can be decreased when it is combined with Tocilizumab.
FluvastatinThe serum concentration of Fluvastatin can be decreased when it is combined with Tocilizumab.
FosamprenavirThe serum concentration of Fosamprenavir can be decreased when it is combined with Tocilizumab.
FulvestrantThe serum concentration of Fulvestrant can be decreased when it is combined with Tocilizumab.
GalantamineThe serum concentration of Galantamine can be decreased when it is combined with Tocilizumab.
GefitinibThe serum concentration of Gefitinib can be decreased when it is combined with Tocilizumab.
GemfibrozilThe serum concentration of Gemfibrozil can be decreased when it is combined with Tocilizumab.
GlipizideThe serum concentration of Glipizide can be decreased when it is combined with Tocilizumab.
GlyburideThe serum concentration of Glyburide can be decreased when it is combined with Tocilizumab.
GolimumabTocilizumab may increase the immunosuppressive activities of Golimumab.
GranisetronThe serum concentration of Granisetron can be decreased when it is combined with Tocilizumab.
GrepafloxacinThe serum concentration of Grepafloxacin can be decreased when it is combined with Tocilizumab.
GuanfacineThe serum concentration of Guanfacine can be decreased when it is combined with Tocilizumab.
HalofantrineThe serum concentration of Halofantrine can be decreased when it is combined with Tocilizumab.
HaloperidolThe serum concentration of Haloperidol can be decreased when it is combined with Tocilizumab.
HalothaneThe serum concentration of Halothane can be decreased when it is combined with Tocilizumab.
HexobarbitalThe serum concentration of Hexobarbital can be decreased when it is combined with Tocilizumab.
Histamine PhosphateThe serum concentration of Histamine Phosphate can be decreased when it is combined with Tocilizumab.
HydrocodoneThe serum concentration of Hydrocodone can be decreased when it is combined with Tocilizumab.
HydrocortisoneThe serum concentration of Hydrocortisone can be decreased when it is combined with Tocilizumab.
HydromorphoneThe serum concentration of Hydromorphone can be decreased when it is combined with Tocilizumab.
Hydroxyprogesterone caproateThe serum concentration of Hydroxyprogesterone caproate can be decreased when it is combined with Tocilizumab.
IbrutinibThe serum concentration of Ibrutinib can be decreased when it is combined with Tocilizumab.
IfosfamideThe serum concentration of Ifosfamide can be decreased when it is combined with Tocilizumab.
IloperidoneThe serum concentration of Iloperidone can be decreased when it is combined with Tocilizumab.
ImatinibThe serum concentration of Imatinib can be decreased when it is combined with Tocilizumab.
ImipramineThe serum concentration of Imipramine can be decreased when it is combined with Tocilizumab.
ImiquimodThe serum concentration of Imiquimod can be decreased when it is combined with Tocilizumab.
IndacaterolThe serum concentration of Indacaterol can be decreased when it is combined with Tocilizumab.
IndapamideThe serum concentration of Indapamide can be decreased when it is combined with Tocilizumab.
IndinavirThe serum concentration of Indinavir can be decreased when it is combined with Tocilizumab.
InfliximabTocilizumab may increase the immunosuppressive activities of Infliximab.
Ipratropium bromideThe serum concentration of Ipratropium bromide can be decreased when it is combined with Tocilizumab.
IrinotecanThe serum concentration of Irinotecan can be decreased when it is combined with Tocilizumab.
IsavuconazoniumThe serum concentration of Isavuconazonium can be decreased when it is combined with Tocilizumab.
Isosorbide DinitrateThe serum concentration of Isosorbide Dinitrate can be decreased when it is combined with Tocilizumab.
Isosorbide MononitrateThe serum concentration of Isosorbide Mononitrate can be decreased when it is combined with Tocilizumab.
IsradipineThe serum concentration of Isradipine can be decreased when it is combined with Tocilizumab.
ItraconazoleThe serum concentration of Itraconazole can be decreased when it is combined with Tocilizumab.
IvabradineThe serum concentration of Ivabradine can be decreased when it is combined with Tocilizumab.
IvacaftorThe serum concentration of Ivacaftor can be decreased when it is combined with Tocilizumab.
IvermectinThe serum concentration of Ivermectin can be decreased when it is combined with Tocilizumab.
IxabepiloneThe serum concentration of Ixabepilone can be decreased when it is combined with Tocilizumab.
IxazomibThe serum concentration of Ixazomib can be decreased when it is combined with Tocilizumab.
KetamineThe serum concentration of Ketamine can be decreased when it is combined with Tocilizumab.
KetazolamThe serum concentration of Ketazolam can be decreased when it is combined with Tocilizumab.
KetobemidoneThe serum concentration of Ketobemidone can be decreased when it is combined with Tocilizumab.
KetoconazoleThe serum concentration of Ketoconazole can be decreased when it is combined with Tocilizumab.
LansoprazoleThe serum concentration of Lansoprazole can be decreased when it is combined with Tocilizumab.
LapatinibThe serum concentration of Lapatinib can be decreased when it is combined with Tocilizumab.
LaquinimodThe serum concentration of Laquinimod can be decreased when it is combined with Tocilizumab.
LeflunomideThe risk or severity of adverse effects can be increased when Tocilizumab is combined with Leflunomide.
LenvatinibThe serum concentration of Lenvatinib can be decreased when it is combined with Tocilizumab.
LercanidipineThe serum concentration of Lercanidipine can be decreased when it is combined with Tocilizumab.
LetrozoleThe serum concentration of Letrozole can be decreased when it is combined with Tocilizumab.
LevobupivacaineThe serum concentration of Levobupivacaine can be decreased when it is combined with Tocilizumab.
LevocetirizineThe serum concentration of Levocetirizine can be decreased when it is combined with Tocilizumab.
Levomethadyl AcetateThe serum concentration of Levomethadyl Acetate can be decreased when it is combined with Tocilizumab.
LevomilnacipranThe serum concentration of Levomilnacipran can be decreased when it is combined with Tocilizumab.
LevonorgestrelThe serum concentration of Levonorgestrel can be decreased when it is combined with Tocilizumab.
LevothyroxineThe serum concentration of Levothyroxine can be decreased when it is combined with Tocilizumab.
LidocaineThe serum concentration of Lidocaine can be decreased when it is combined with Tocilizumab.
LisurideThe serum concentration of Lisuride can be decreased when it is combined with Tocilizumab.
LomitapideThe serum concentration of Lomitapide can be decreased when it is combined with Tocilizumab.
LoperamideThe serum concentration of Loperamide can be decreased when it is combined with Tocilizumab.
LopinavirThe serum concentration of Lopinavir can be decreased when it is combined with Tocilizumab.
LoratadineThe serum concentration of Loratadine can be decreased when it is combined with Tocilizumab.
LorcaserinThe serum concentration of Lorcaserin can be decreased when it is combined with Tocilizumab.
LosartanThe serum concentration of Losartan can be decreased when it is combined with Tocilizumab.
LovastatinThe serum concentration of Lovastatin can be decreased when it is combined with Tocilizumab.
LumefantrineThe serum concentration of Lumefantrine can be decreased when it is combined with Tocilizumab.
LurasidoneThe serum concentration of Lurasidone can be decreased when it is combined with Tocilizumab.
MacitentanThe serum concentration of Macitentan can be decreased when it is combined with Tocilizumab.
MaravirocThe serum concentration of Maraviroc can be decreased when it is combined with Tocilizumab.
MebendazoleThe serum concentration of Mebendazole can be decreased when it is combined with Tocilizumab.
Medroxyprogesterone acetateThe serum concentration of Medroxyprogesterone acetate can be decreased when it is combined with Tocilizumab.
MefloquineThe serum concentration of Mefloquine can be decreased when it is combined with Tocilizumab.
MeloxicamThe serum concentration of Meloxicam can be decreased when it is combined with Tocilizumab.
MethadoneThe serum concentration of Methadone can be decreased when it is combined with Tocilizumab.
MethaqualoneThe serum concentration of Methaqualone can be decreased when it is combined with Tocilizumab.
MethoxsalenThe serum concentration of Methoxsalen can be decreased when it is combined with Tocilizumab.
MethoxyfluraneThe serum concentration of Methoxyflurane can be decreased when it is combined with Tocilizumab.
MethylprednisoloneThe serum concentration of Methylprednisolone can be decreased when it is combined with Tocilizumab.
MethyltestosteroneThe serum concentration of Methyltestosterone can be decreased when it is combined with Tocilizumab.
MetronidazoleThe serum concentration of Metronidazole can be decreased when it is combined with Tocilizumab.
MexiletineThe serum concentration of Mexiletine can be decreased when it is combined with Tocilizumab.
MianserinThe serum concentration of Mianserin can be decreased when it is combined with Tocilizumab.
MibefradilThe serum concentration of Mibefradil can be decreased when it is combined with Tocilizumab.
MiconazoleThe serum concentration of Miconazole can be decreased when it is combined with Tocilizumab.
MidazolamThe serum concentration of Midazolam can be decreased when it is combined with Tocilizumab.
MifepristoneThe serum concentration of Mifepristone can be decreased when it is combined with Tocilizumab.
MirabegronThe serum concentration of Mirabegron can be decreased when it is combined with Tocilizumab.
MirtazapineThe serum concentration of Mirtazapine can be decreased when it is combined with Tocilizumab.
ModafinilThe serum concentration of Modafinil can be decreased when it is combined with Tocilizumab.
MontelukastThe serum concentration of Montelukast can be decreased when it is combined with Tocilizumab.
MorphineThe serum concentration of Morphine can be decreased when it is combined with Tocilizumab.
Mycophenolate mofetilThe serum concentration of Mycophenolate mofetil can be decreased when it is combined with Tocilizumab.
NaloxegolThe serum concentration of Naloxegol can be decreased when it is combined with Tocilizumab.
NaloxoneThe serum concentration of Naloxone can be decreased when it is combined with Tocilizumab.
NatalizumabThe risk or severity of adverse effects can be increased when Tocilizumab is combined with Natalizumab.
NateglinideThe serum concentration of Nateglinide can be decreased when it is combined with Tocilizumab.
NefazodoneThe serum concentration of Nefazodone can be decreased when it is combined with Tocilizumab.
NelfinavirThe serum concentration of Nelfinavir can be decreased when it is combined with Tocilizumab.
NevirapineThe serum concentration of Nevirapine can be decreased when it is combined with Tocilizumab.
NicardipineThe serum concentration of Nicardipine can be decreased when it is combined with Tocilizumab.
NicotineThe serum concentration of Nicotine can be decreased when it is combined with Tocilizumab.
NifedipineThe serum concentration of Nifedipine can be decreased when it is combined with Tocilizumab.
NilotinibThe serum concentration of Nilotinib can be decreased when it is combined with Tocilizumab.
NilvadipineThe serum concentration of Nilvadipine can be decreased when it is combined with Tocilizumab.
NimodipineThe serum concentration of Nimodipine can be decreased when it is combined with Tocilizumab.
NisoldipineThe serum concentration of Nisoldipine can be decreased when it is combined with Tocilizumab.
NitrazepamThe serum concentration of Nitrazepam can be decreased when it is combined with Tocilizumab.
NitrendipineThe serum concentration of Nitrendipine can be decreased when it is combined with Tocilizumab.
NorethisteroneThe serum concentration of Norethisterone can be decreased when it is combined with Tocilizumab.
NorgestrelThe serum concentration of Norgestrel can be decreased when it is combined with Tocilizumab.
NortriptylineThe serum concentration of Nortriptyline can be decreased when it is combined with Tocilizumab.
OlaparibThe serum concentration of Olaparib can be decreased when it is combined with Tocilizumab.
OlopatadineThe serum concentration of Olopatadine can be decreased when it is combined with Tocilizumab.
OmeprazoleThe serum concentration of Omeprazole can be decreased when it is combined with Tocilizumab.
OndansetronThe serum concentration of Ondansetron can be decreased when it is combined with Tocilizumab.
OrphenadrineThe serum concentration of Orphenadrine can be decreased when it is combined with Tocilizumab.
OspemifeneThe serum concentration of Ospemifene can be decreased when it is combined with Tocilizumab.
OxazepamThe serum concentration of Oxazepam can be decreased when it is combined with Tocilizumab.
OxybutyninThe serum concentration of Oxybutynin can be decreased when it is combined with Tocilizumab.
OxycodoneThe serum concentration of Oxycodone can be decreased when it is combined with Tocilizumab.
OxymorphoneThe serum concentration of Oxymorphone can be decreased when it is combined with Tocilizumab.
PaclitaxelThe serum concentration of Paclitaxel can be decreased when it is combined with Tocilizumab.
PalbociclibThe serum concentration of Palbociclib can be decreased when it is combined with Tocilizumab.
PalonosetronThe serum concentration of Palonosetron can be decreased when it is combined with Tocilizumab.
PanobinostatThe serum concentration of Panobinostat can be decreased when it is combined with Tocilizumab.
PantoprazoleThe serum concentration of Pantoprazole can be decreased when it is combined with Tocilizumab.
ParamethadioneThe serum concentration of Paramethadione can be decreased when it is combined with Tocilizumab.
ParamethasoneThe serum concentration of Paramethasone can be decreased when it is combined with Tocilizumab.
ParecoxibThe serum concentration of Parecoxib can be decreased when it is combined with Tocilizumab.
ParicalcitolThe serum concentration of Paricalcitol can be decreased when it is combined with Tocilizumab.
ParitaprevirThe serum concentration of Paritaprevir can be decreased when it is combined with Tocilizumab.
PazopanibThe serum concentration of Pazopanib can be decreased when it is combined with Tocilizumab.
PentamidineThe serum concentration of Pentamidine can be decreased when it is combined with Tocilizumab.
PerampanelThe serum concentration of Perampanel can be decreased when it is combined with Tocilizumab.
PergolideThe serum concentration of Pergolide can be decreased when it is combined with Tocilizumab.
PerhexilineThe serum concentration of Perhexiline can be decreased when it is combined with Tocilizumab.
PermethrinThe serum concentration of Permethrin can be decreased when it is combined with Tocilizumab.
PerphenazineThe serum concentration of Perphenazine can be decreased when it is combined with Tocilizumab.
PethidineThe serum concentration of Pethidine can be decreased when it is combined with Tocilizumab.
PhenacetinThe serum concentration of Phenacetin can be decreased when it is combined with Tocilizumab.
PhenoxybenzamineThe serum concentration of Phenoxybenzamine can be decreased when it is combined with Tocilizumab.
PhenprocoumonThe serum concentration of Phenprocoumon can be decreased when it is combined with Tocilizumab.
PhenytoinThe serum concentration of Phenytoin can be decreased when it is combined with Tocilizumab.
PilocarpineThe serum concentration of Pilocarpine can be decreased when it is combined with Tocilizumab.
PimecrolimusThe risk or severity of adverse effects can be increased when Pimecrolimus is combined with Tocilizumab.
PimecrolimusThe serum concentration of Pimecrolimus can be decreased when it is combined with Tocilizumab.
PimozideThe serum concentration of Pimozide can be decreased when it is combined with Tocilizumab.
PinacidilThe serum concentration of Pinacidil can be decreased when it is combined with Tocilizumab.
PioglitazoneThe serum concentration of Pioglitazone can be decreased when it is combined with Tocilizumab.
PipotiazineThe serum concentration of Pipotiazine can be decreased when it is combined with Tocilizumab.
PirfenidoneTocilizumab may increase the immunosuppressive activities of Pirfenidone.
PodofiloxThe serum concentration of Podofilox can be decreased when it is combined with Tocilizumab.
PomalidomideThe serum concentration of Pomalidomide can be decreased when it is combined with Tocilizumab.
PonatinibThe serum concentration of Ponatinib can be decreased when it is combined with Tocilizumab.
PosaconazoleThe serum concentration of Posaconazole can be decreased when it is combined with Tocilizumab.
PrasugrelThe serum concentration of Prasugrel can be decreased when it is combined with Tocilizumab.
PravastatinThe serum concentration of Pravastatin can be decreased when it is combined with Tocilizumab.
PrazepamThe serum concentration of Prazepam can be decreased when it is combined with Tocilizumab.
PraziquantelThe serum concentration of Praziquantel can be decreased when it is combined with Tocilizumab.
PrednisoloneThe serum concentration of Prednisolone can be decreased when it is combined with Tocilizumab.
PrednisoneThe serum concentration of Prednisone can be decreased when it is combined with Tocilizumab.
PrimaquineThe serum concentration of Primaquine can be decreased when it is combined with Tocilizumab.
ProchlorperazineThe serum concentration of Prochlorperazine can be decreased when it is combined with Tocilizumab.
ProgesteroneThe serum concentration of Progesterone can be decreased when it is combined with Tocilizumab.
ProguanilThe serum concentration of Proguanil can be decreased when it is combined with Tocilizumab.
PromazineThe serum concentration of Promazine can be decreased when it is combined with Tocilizumab.
PropafenoneThe serum concentration of Propafenone can be decreased when it is combined with Tocilizumab.
PropofolThe serum concentration of Propofol can be decreased when it is combined with Tocilizumab.
PropranololThe serum concentration of Propranolol can be decreased when it is combined with Tocilizumab.
PyrazinamideThe serum concentration of Pyrazinamide can be decreased when it is combined with Tocilizumab.
QuazepamThe serum concentration of Quazepam can be decreased when it is combined with Tocilizumab.
QuetiapineThe serum concentration of Quetiapine can be decreased when it is combined with Tocilizumab.
QuinacrineThe serum concentration of Quinacrine can be decreased when it is combined with Tocilizumab.
QuinidineThe serum concentration of Quinidine can be decreased when it is combined with Tocilizumab.
QuinineThe serum concentration of Quinine can be decreased when it is combined with Tocilizumab.
RabeprazoleThe serum concentration of Rabeprazole can be decreased when it is combined with Tocilizumab.
Rabies vaccineThe risk or severity of adverse effects can be increased when Tocilizumab is combined with Rabies vaccine.
RaloxifeneThe serum concentration of Raloxifene can be decreased when it is combined with Tocilizumab.
RamelteonThe serum concentration of Ramelteon can be decreased when it is combined with Tocilizumab.
RanolazineThe serum concentration of Ranolazine can be decreased when it is combined with Tocilizumab.
ReboxetineThe serum concentration of Reboxetine can be decreased when it is combined with Tocilizumab.
RegorafenibThe serum concentration of Regorafenib can be decreased when it is combined with Tocilizumab.
RepaglinideThe serum concentration of Repaglinide can be decreased when it is combined with Tocilizumab.
RetapamulinThe serum concentration of Retapamulin can be decreased when it is combined with Tocilizumab.
RifabutinThe serum concentration of Rifabutin can be decreased when it is combined with Tocilizumab.
RifampicinThe serum concentration of Rifampicin can be decreased when it is combined with Tocilizumab.
RilpivirineThe serum concentration of Rilpivirine can be decreased when it is combined with Tocilizumab.
RimonabantThe serum concentration of Rimonabant can be decreased when it is combined with Tocilizumab.
RiociguatThe serum concentration of Riociguat can be decreased when it is combined with Tocilizumab.
RisperidoneThe serum concentration of Risperidone can be decreased when it is combined with Tocilizumab.
RitonavirThe serum concentration of Ritonavir can be decreased when it is combined with Tocilizumab.
RivaroxabanThe serum concentration of Rivaroxaban can be decreased when it is combined with Tocilizumab.
RofecoxibThe serum concentration of Rofecoxib can be decreased when it is combined with Tocilizumab.
RoflumilastRoflumilast may increase the immunosuppressive activities of Tocilizumab.
RolapitantThe serum concentration of Rolapitant can be decreased when it is combined with Tocilizumab.
RomidepsinThe serum concentration of Romidepsin can be decreased when it is combined with Tocilizumab.
RopiniroleThe serum concentration of Ropinirole can be decreased when it is combined with Tocilizumab.
RopivacaineThe serum concentration of Ropivacaine can be decreased when it is combined with Tocilizumab.
RosuvastatinThe serum concentration of Rosuvastatin can be decreased when it is combined with Tocilizumab.
RotigotineThe serum concentration of Rotigotine can be decreased when it is combined with Tocilizumab.
RoxithromycinThe serum concentration of Roxithromycin can be decreased when it is combined with Tocilizumab.
RuxolitinibThe serum concentration of Ruxolitinib can be decreased when it is combined with Tocilizumab.
SalmeterolThe serum concentration of Salmeterol can be decreased when it is combined with Tocilizumab.
SaquinavirThe serum concentration of Saquinavir can be decreased when it is combined with Tocilizumab.
SaxagliptinThe serum concentration of Saxagliptin can be decreased when it is combined with Tocilizumab.
SelegilineThe serum concentration of Selegiline can be decreased when it is combined with Tocilizumab.
SelexipagThe serum concentration of Selexipag can be decreased when it is combined with Tocilizumab.
SeratrodastThe serum concentration of Seratrodast can be decreased when it is combined with Tocilizumab.
SertindoleThe serum concentration of Sertindole can be decreased when it is combined with Tocilizumab.
SertralineThe serum concentration of Sertraline can be decreased when it is combined with Tocilizumab.
SevofluraneThe serum concentration of Sevoflurane can be decreased when it is combined with Tocilizumab.
SibutramineThe serum concentration of Sibutramine can be decreased when it is combined with Tocilizumab.
SildenafilThe serum concentration of Sildenafil can be decreased when it is combined with Tocilizumab.
SilodosinThe serum concentration of Silodosin can be decreased when it is combined with Tocilizumab.
SimeprevirThe serum concentration of Simeprevir can be decreased when it is combined with Tocilizumab.
SimvastatinThe serum concentration of Simvastatin can be decreased when it is combined with Tocilizumab.
Sipuleucel-TThe therapeutic efficacy of Sipuleucel-T can be decreased when used in combination with Tocilizumab.
SirolimusThe serum concentration of Sirolimus can be decreased when it is combined with Tocilizumab.
SitagliptinThe serum concentration of Sitagliptin can be decreased when it is combined with Tocilizumab.
SolifenacinThe serum concentration of Solifenacin can be decreased when it is combined with Tocilizumab.
SonidegibThe serum concentration of Sonidegib can be decreased when it is combined with Tocilizumab.
SorafenibThe serum concentration of Sorafenib can be decreased when it is combined with Tocilizumab.
SpiramycinThe serum concentration of Spiramycin can be decreased when it is combined with Tocilizumab.
SufentanilThe serum concentration of Sufentanil can be decreased when it is combined with Tocilizumab.
SulfadiazineThe serum concentration of Sulfadiazine can be decreased when it is combined with Tocilizumab.
SulfamethoxazoleThe serum concentration of Sulfamethoxazole can be decreased when it is combined with Tocilizumab.
SulfinpyrazoneThe serum concentration of Sulfinpyrazone can be decreased when it is combined with Tocilizumab.
SunitinibThe serum concentration of Sunitinib can be decreased when it is combined with Tocilizumab.
Synthetic Conjugated Estrogens, AThe serum concentration of Synthetic Conjugated Estrogens, A can be decreased when it is combined with Tocilizumab.
Synthetic Conjugated Estrogens, BThe serum concentration of Synthetic Conjugated Estrogens, B can be decreased when it is combined with Tocilizumab.
TacrolimusThe serum concentration of Tacrolimus can be decreased when it is combined with Tocilizumab.
TacrolimusThe risk or severity of adverse effects can be increased when Tacrolimus is combined with Tocilizumab.
TadalafilThe serum concentration of Tadalafil can be decreased when it is combined with Tocilizumab.
TamoxifenThe serum concentration of Tamoxifen can be decreased when it is combined with Tocilizumab.
TamsulosinThe serum concentration of Tamsulosin can be decreased when it is combined with Tocilizumab.
TasosartanThe serum concentration of Tasosartan can be decreased when it is combined with Tocilizumab.
Taurochenodeoxycholic acidThe serum concentration of Taurochenodeoxycholic acid can be decreased when it is combined with Tocilizumab.
TelaprevirThe serum concentration of Telaprevir can be decreased when it is combined with Tocilizumab.
TelithromycinThe serum concentration of Telithromycin can be decreased when it is combined with Tocilizumab.
TemazepamThe serum concentration of Temazepam can be decreased when it is combined with Tocilizumab.
TemsirolimusThe serum concentration of Temsirolimus can be decreased when it is combined with Tocilizumab.
TeniposideThe serum concentration of Teniposide can be decreased when it is combined with Tocilizumab.
TerbinafineThe serum concentration of Terbinafine can be decreased when it is combined with Tocilizumab.
TerfenadineThe serum concentration of Terfenadine can be decreased when it is combined with Tocilizumab.
TesmilifeneThe serum concentration of Tesmilifene can be decreased when it is combined with Tocilizumab.
TestosteroneThe serum concentration of Testosterone can be decreased when it is combined with Tocilizumab.
TetracyclineThe serum concentration of Tetracycline can be decreased when it is combined with Tocilizumab.
TheophyllineThe serum concentration of Theophylline can be decreased when it is combined with Tocilizumab.
ThiotepaThe serum concentration of Thiotepa can be decreased when it is combined with Tocilizumab.
TiagabineThe serum concentration of Tiagabine can be decreased when it is combined with Tocilizumab.
TicagrelorThe serum concentration of Ticagrelor can be decreased when it is combined with Tocilizumab.
TiclopidineThe serum concentration of Ticlopidine can be decreased when it is combined with Tocilizumab.
TinidazoleThe serum concentration of Tinidazole can be decreased when it is combined with Tocilizumab.
TiotropiumThe serum concentration of Tiotropium can be decreased when it is combined with Tocilizumab.
TipranavirThe serum concentration of Tipranavir can be decreased when it is combined with Tocilizumab.
TofacitinibTocilizumab may increase the immunosuppressive activities of Tofacitinib.
TolterodineThe serum concentration of Tolterodine can be decreased when it is combined with Tocilizumab.
TolvaptanThe serum concentration of Tolvaptan can be decreased when it is combined with Tocilizumab.
ToremifeneThe serum concentration of Toremifene can be decreased when it is combined with Tocilizumab.
TrabectedinThe serum concentration of Trabectedin can be decreased when it is combined with Tocilizumab.
TramadolThe serum concentration of Tramadol can be decreased when it is combined with Tocilizumab.
TrastuzumabTrastuzumab may increase the neutropenic activities of Tocilizumab.
Trastuzumab emtansineThe serum concentration of Trastuzumab emtansine can be decreased when it is combined with Tocilizumab.
TrazodoneThe serum concentration of Trazodone can be decreased when it is combined with Tocilizumab.
TretinoinThe serum concentration of Tretinoin can be decreased when it is combined with Tocilizumab.
TriamcinoloneThe serum concentration of Triamcinolone can be decreased when it is combined with Tocilizumab.
TriazolamThe serum concentration of Triazolam can be decreased when it is combined with Tocilizumab.
TrimethadioneThe serum concentration of Trimethadione can be decreased when it is combined with Tocilizumab.
TrimethoprimThe serum concentration of Trimethoprim can be decreased when it is combined with Tocilizumab.
TrimipramineThe serum concentration of Trimipramine can be decreased when it is combined with Tocilizumab.
TroglitazoneThe serum concentration of Troglitazone can be decreased when it is combined with Tocilizumab.
TroleandomycinThe serum concentration of Troleandomycin can be decreased when it is combined with Tocilizumab.
UdenafilThe serum concentration of Udenafil can be decreased when it is combined with Tocilizumab.
UlipristalThe serum concentration of Ulipristal can be decreased when it is combined with Tocilizumab.
ValdecoxibThe serum concentration of Valdecoxib can be decreased when it is combined with Tocilizumab.
VandetanibThe serum concentration of Vandetanib can be decreased when it is combined with Tocilizumab.
VanoxerineThe serum concentration of Vanoxerine can be decreased when it is combined with Tocilizumab.
VardenafilThe serum concentration of Vardenafil can be decreased when it is combined with Tocilizumab.
VemurafenibThe serum concentration of Vemurafenib can be decreased when it is combined with Tocilizumab.
VenlafaxineThe serum concentration of Venlafaxine can be decreased when it is combined with Tocilizumab.
VerapamilThe serum concentration of Verapamil can be decreased when it is combined with Tocilizumab.
VicrivirocThe serum concentration of Vicriviroc can be decreased when it is combined with Tocilizumab.
VilanterolThe serum concentration of Vilanterol can be decreased when it is combined with Tocilizumab.
VilazodoneThe serum concentration of Vilazodone can be decreased when it is combined with Tocilizumab.
VinblastineThe serum concentration of Vinblastine can be decreased when it is combined with Tocilizumab.
VincristineThe serum concentration of Vincristine can be decreased when it is combined with Tocilizumab.
VindesineThe serum concentration of Vindesine can be decreased when it is combined with Tocilizumab.
VinorelbineThe serum concentration of Vinorelbine can be decreased when it is combined with Tocilizumab.
VismodegibThe serum concentration of Vismodegib can be decreased when it is combined with Tocilizumab.
VoriconazoleThe serum concentration of Voriconazole can be decreased when it is combined with Tocilizumab.
VortioxetineThe serum concentration of Vortioxetine can be decreased when it is combined with Tocilizumab.
WarfarinThe serum concentration of Warfarin can be decreased when it is combined with Tocilizumab.
YohimbineThe serum concentration of Yohimbine can be decreased when it is combined with Tocilizumab.
ZafirlukastThe serum concentration of Zafirlukast can be decreased when it is combined with Tocilizumab.
ZalcitabineThe serum concentration of Zalcitabine can be decreased when it is combined with Tocilizumab.
ZaleplonThe serum concentration of Zaleplon can be decreased when it is combined with Tocilizumab.
ZidovudineThe serum concentration of Zidovudine can be decreased when it is combined with Tocilizumab.
ZileutonThe serum concentration of Zileuton can be decreased when it is combined with Tocilizumab.
ZiprasidoneThe serum concentration of Ziprasidone can be decreased when it is combined with Tocilizumab.
ZolpidemThe serum concentration of Zolpidem can be decreased when it is combined with Tocilizumab.
ZomepiracThe serum concentration of Zomepirac can be decreased when it is combined with Tocilizumab.
ZonisamideThe serum concentration of Zonisamide can be decreased when it is combined with Tocilizumab.
ZopicloneThe serum concentration of Zopiclone can be decreased when it is combined with Tocilizumab.
Food InteractionsNot Available

Targets

Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
antibody
General Function:
Protein homodimerization activity
Specific Function:
Part of the receptor for interleukin 6. Binds to IL6 with low affinity, but does not transduce a signal. Signal activation necessitate an association with IL6ST. Activation may lead to the regulation of the immune response, acute-phase reactions and hematopoiesis.Low concentration of a soluble form of IL6 receptor acts as an agonist of IL6 activity.
Gene Name:
IL6R
Uniprot ID:
P08887
Molecular Weight:
51547.015 Da
References
  1. Smolen JS, Maini RN: Interleukin-6: a new therapeutic target. Arthritis Res Ther. 2006;8 Suppl 2:S5. Epub 2006 Jul 28. [PubMed:16899109 ]
Comments
comments powered by Disqus
Drug created on March 19, 2008 10:20 / Updated on August 17, 2016 12:24